IPO Boutique Research, Color & More Information for Subscribers
This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]
This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]
While IPO issuance up to this point have been slower than last year, the underwriters have not been afraid to bring out follow-on offerings. A total of 25 secondary’s were priced for the week of February 23rd which totaled in the multi-billions including a record-breaking offering from Actavis (NYSE: ACT). “Based upon the lack of[…]
This past week two IPOs debuted, zero updated terms and six new deals filed. It was week that produced very little fanfare as the deals that came to market, Inotek Pharmaceuticals (Nasdaq: ITEK) and Check-Cap Limited (Nasdaq: CHEKU) were holdovers from the previous week. Inotek was able to come to market after severely slashing their[…]
Wednesday Wowo Limited (Nasdaq: WOWO) – Axiom is running the deal that is to sell 6.0 million shares at an initial range of $9.00-$11.00. Friday Actavis (Nasdaq: ACT) – The company is pursuing a secondary with concurrent offerings totaling $8.4 billion, comprising $4.2 billion of Ordinary Shares and $4.2 billion of Mandatory Convertible Preferred Shares,[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Actavis Symbol: ACT Price: Last trade $284.00 Trade Date: 2/27 Shares: 14.79 million Underwriter(s) J.P. Morgan, Mizuho Securities, Wells Fargo Securities,[…]